Loading
A phase 1/2 trial of Petosemtamab, Pembrolizumab, FOLFIRI in colorectal cancer and head and neck squamous cell carcinoma, run by Merus B.V., now recruiting.
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03526835 by Merus B.V., with 560 participants planned, started 2018-05-02 and due to reach its primary completion in 2028-05. Interventions recorded: MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX. Conditions listed: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Petosemtamab, Genmab, FOLFIRI (5-FU, leucovorin, irinotecan), Bispecific antibodies.
Shares Petosemtamab, Genmab, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares Petosemtamab, Genmab, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares Petosemtamab, Genmab, Bispecific antibodies, Colorectal cancer.
Shares Petosemtamab, Head and neck squamous cell carcinoma, Colorectal cancer.
Shares Genmab, Head and neck squamous cell carcinoma, Pembrolizumab, Colorectal cancer.
Shares Genmab, Head and neck squamous cell carcinoma, Pembrolizumab, Colorectal cancer.
Shares Genmab, Head and neck squamous cell carcinoma, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/